Addressing unmet needs with urological therapies

Urology is a focus area of highest importance for us at medac. We have been active in this field from almost the very beginning of our company in the 1970s. As an internationally growing pharmaceutical company dedicated to improving human health, particularly in areas of high therapeutic needs, we are focused on supplying a range of products that address a variety of unmet therapeutic needs.
Addressing unmet needs with urological therapies

Focussing on bladder cancer

Our work in urology is a well-proven example of how we successfully pursue our mission. The therapeutic niche we focus on is non-muscle invasive bladder cancer (NMIBC), specifically the adjuvant treatment in the first-line setting. As early as the end of the 19th century, it was observed that the tumours in some cancer patients shrank when they suffered from a high fever caused by a bacterial infection. This paved the way for the immunotherapy of cancer, where treatments specifically stimulate the body's own immune system and help it fight against the tumour – ultimately reducing the burden from the tumour.

Instillation therapy with medac

Instillation therapies in non-muscle invasive bladder cancer (NMIBC) have a long tradition at medac. With two well-established medications, we provide a dual first-line treatment concept for the adjuvant treatment of NMIBC. Powered by the needs of the users and to increase their personal safety, our experts developed the first closed instillation system in the market in 1988.

Today our system comes as standard with our compounds and is highly regarded for its ease of use and safety by healthcare professionals from all over the world. 

Providing reliability in an undersupplied market

By continually developing our expertise over many years, we have been able to reliably serve the undersupplied NMIBC market with preparations for all risk classes, making our products available to patients in need.

Reporting an adverse event

Apart from the desired effects, medical products can have side effects that are unpleasant or unintended. At medac, we continually collate information about side effects in order to monitor the benefit risk balance of each medication throughout its marketing lifecycle, and if necessary, can take action to better protect patient safety.

Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to medac Pharma at info@medacpharma.co.uk

We may contact you to gain further details about the report. However we are unable to provide medical advice. If you are concerned about any aspect of your treatment please discuss this with your healthcare professional (such as a doctor, nurse or pharmacist).



Please enter your email address and password to log in.